We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
-11.41%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$1.36B
AUM Growth
-$498M
Cap. Flow
-$243M
Cap. Flow %
-17.89%
Top 10 Hldgs %
76.48%
Holding
31
New
2
Increased
13
Reduced
4
Closed
7

Top Buys

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$81.7M
2
EXEL icon
Exelixis
EXEL
+$49.3M
3
UTHR icon
United Therapeutics
UTHR
+$27.6M
4
MYGN icon
Myriad Genetics
MYGN
+$26M
5
QURE icon
uniQure
QURE
+$23.7M

Top Sells

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$106M
2
NVRO
NEVRO CORP.
NVRO
+$82.4M
3
NUVA
NuVasive, Inc.
NUVA
+$77.3M
4
PACB icon
Pacific Biosciences
PACB
+$70.1M
5
VSTM icon
Verastem
VSTM
+$37.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCRX icon
1
Pacira BioSciences
PCRX
$1.06B
$157M 11.56%
3,652,134
– –
EXEL icon
2
Exelixis
EXEL
$14.1B
$131M 9.61%
6,645,113
+2,766,063
+71% +$49.3M
AMRN
3
Amarin Corp
AMRN
$298M
$129M 9.46%
472,538
+224,105
+90% +$81.7M
VNDA icon
4
Vanda Pharmaceuticals
VNDA
$312M
$122M 8.95%
4,658,759
+215,000
+5% +$5.06M
UTHR icon
5
United Therapeutics
UTHR
$26.2B
$120M 8.81%
1,100,597
+238,302
+28% +$27.6M
TVTX icon
6
Travere Therapeutics
TVTX
$5.33B
$91.2M 6.71%
4,032,123
+117,941
+3% +$2.93M
CORT icon
7
Corcept Therapeutics
CORT
$12.7B
$83M 6.1%
6,211,964
+1,173,090
+23% +$15.5M
VCEL icon
8
Vericel Corp
VCEL
$2.43B
$73.4M 5.4%
4,218,092
+50,000
+1% +$748K
MYGN icon
9
Myriad Genetics
MYGN
$507M
$68.9M 5.07%
2,370,296
+723,966
+44% +$26M
URGN icon
10
UroGen Pharma
URGN
$2B
$65.3M 4.8%
1,515,422
– –
LMNX
11
DELISTED
Luminex Corp
LMNX
$55.5M 4.08%
2,402,787
+33,779
+1% +$910K
QURE icon
12
uniQure
QURE
$2.93B
$54.6M 4.02%
1,896,226
+851,161
+81% +$23.7M
KPTI icon
13
Karyopharm Therapeutics
KPTI
$159M
$45.1M 3.31%
320,672
-1,133
-0.4% -$191K
OXFD
14
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$33M 2.42%
2,579,784
+130,600
+5% +$1.98M
SPPI
15
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$26M 1.91%
2,969,027
-2,860,851
-49% -$36.4M
SVRA icon
16
Savara
SVRA
$1.14B
$23.4M 1.72%
3,093,690
– –
PACB icon
17
Pacific Biosciences
PACB
$460M
$18.2M 1.34%
2,455,114
-11,057,844
-82% -$70.1M
CPRX
18
DELISTED
Catalyst Pharmaceutical
CPRX
$18.1M 1.33%
9,402,317
+3,357,598
+56% +$9.61M
STML
19
DELISTED
Stemline Therapeutics, Inc.
STML
$11M 0.81%
1,155,793
-1,591,405
-58% -$20.6M
ADMA icon
20
ADMA Biologics
ADMA
$2.01B
$11M 0.81%
4,588,352
+49,057
+1% +$243K
CARM
21
DELISTED
Carisma Therapeutics
CARM
$10.7M 0.79%
376,165
– –
ANIP icon
22
ANI Pharmaceuticals
ANIP
$1.83B
$6.43M 0.47%
142,943
– –
AUPH icon
23
Aurinia Pharmaceuticals
AUPH
$1.93B
$68K 0.01%
+10,000
New +$57.7K
INVA icon
24
Innoviva
INVA
$1.57B
– –
-1,002,675
Closed -$15.3M
PBYI icon
25
Puma Biotechnology
PBYI
$402M
– –
-2,303,455
Closed -$106M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q4 2018 Portfolio in Review

As of Q4 2018, Consonance Capital Management held 31 positions worth $1.36B, down 27% from $1.86B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Consonance Capital Management withdrew a net $243M in Q4 2018, closing 7 positions and reducing 4 holdings. Its most notable exit was Puma Biotechnology, an estimated $106M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Consonance Capital Management opened a new position in Aurinia Pharmaceuticals worth $68K.

  • Consonance Capital Management's largest Q4 2018 buy was Aurinia Pharmaceuticals: 10,000 shares worth $68K.
  • Consonance Capital Management added most to Amarin Corp in Q4 2018, an estimated $81.7M increase.
  • Consonance Capital Management's biggest Q4 2018 reduction was Pacific Biosciences, cutting an estimated $70.1M.
  • Consonance Capital Management fully exited Puma Biotechnology in Q4 2018, selling an estimated $106M.
  • Consonance Capital Management's ten largest holdings make up 76% of its $1.36B portfolio in Q4 2018.
  • Consonance Capital Management opened 2 new positions and closed 7 in Q4 2018.
  • Consonance Capital Management's portfolio value fell 27% quarter-over-quarter to $1.36B.

Based on Consonance Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.